Ultragenyx to Participate at Citi BioPharma Conference

NOVATO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Eric Crombez, Chief Medical Officer, Gene Therapy, will participate in a Rare Disease Panel at Citi's 17th Annual BioPharma Conference on Wednesday, September 7, 2022, at 11:20 AM ET.

The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts
Ultragenyx Pharmaceutical, Inc.
Investors  
Joshua Higa 
[email protected]  

Media  
Jeff Blake 
415-612-7784 
[email protected]

You May Also Be Interested In

• We The Billions Launches Personalized Cognitive Care Focused on How Each Brain Works
• China has potential to lead global humanoid robotics: Founder of EngineAI
• 4 Top Trending Cryptos to Watch Now: BlockDAG, Solana, Hyperliquid, & Super!